{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:27:13Z","timestamp":1779244033059,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/inf.0000000000001056","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T12:22:53Z","timestamp":1452601373000},"page":"e113-e123","source":"Crossref","is-referenced-by-count":27,"title":["Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age"],"prefix":"10.1097","volume":"35","author":[{"given":"Matthew D.","family":"Snape","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Bona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Diez-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Sokal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Kieninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Prymula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R6-18-20210202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"R8-18-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Child"},{"key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"R11-18-20210202","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"issue":"suppl 2","key":"R12-18-20210202","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/INF.0b013e3181faa6be","article-title":"Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R19-18-20210202","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","article-title":"A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.","volume":"93","author":"Pace","year":"2008","journal-title":"Arch Dis Child"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R22-18-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R23-18-20210202","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.","volume":"32","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R24-18-20210202","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R25-18-20210202","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R26-18-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"R27-18-20210202","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:09:57Z","timestamp":1620954597000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201604000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001056","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}